Miromatrix Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Miromatrix Medical şirketinin toplam hissedar öz sermayesi $15.5M ve toplam borcu $386.0K olup, bu da borç-öz sermaye oranını 2.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $23.4M ve $7.9M dir.

Anahtar bilgiler

2.5%

Borç/özkaynak oranı

US$386.00k

Borç

Faiz karşılama oranı	n/a
Nakit	US$16.06m
Eşitlik	US$15.54m
Toplam yükümlülükler	US$7.88m
Toplam varlıklar	US$23.42m

Son finansal sağlık güncellemeleri

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Oct 28

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

Jul 01

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Mar 08

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Sep 30

Recent updates

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Oct 28

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

Jul 01

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Mar 08

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Sep 30

Miromatrix gets US patent for recellularizing technology for use in organ transplant

Aug 25

Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M

Aug 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MIRO 'nin kısa vadeli varlıkları ( $17.2M ) kısa vadeli yükümlülüklerini ( $5.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: MIRO şirketinin kısa vadeli varlıkları ( $17.2M ) uzun vadeli yükümlülüklerini ( $2.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MIRO şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: MIRO şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MIRO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: MIRO un, serbest nakit akışı her yıl % 36.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Miromatrix Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Miromatrix Medical Inc. Files Form 15

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Recent updates

Miromatrix Medical Inc. Files Form 15

Miromatrix Medical Inc. Announces Directorate Changes

Miromatrix Medical Inc.(NasdaqCM:MIRO) dropped from NASDAQ Composite Index

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

United Therapeutics Corporation (NasdaqGS:UTHR) entered into definitive agreement to acquire Miromatrix Medical Inc. (NasdaqCM:MIRO) from shareholders for $89.1 million.

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Miromatrix Medical Inc. to Report Q2, 2023 Results on Aug 14, 2023

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

New major risk - Share price stability

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Price target decreased by 10.0% to US$13.50

Miromatrix Provides Update on miroliverELAP

Miromatrix Medical Inc. Announces FDA Clinical Hold on IND Application for miroliverELAP

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Miromatrix Medical Inc. to Report Q3, 2022 Results on Nov 14, 2022

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

Miromatrix gets US patent for recellularizing technology for use in organ transplant

Second quarter 2022 earnings released: US$0.40 loss per share (vs US$1.27 loss in 2Q 2021)

Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M

Miromatrix Medical Inc. Appoints Jack Lake, M.D., as Medical Director

Miromatrix Medical Inc. to Report Q2, 2022 Results on Aug 15, 2022

Miromatrix Medical Inc.(NasdaqCM:MIRO) dropped from Russell Microcap Value Index

First quarter 2022 earnings released: US$0.35 loss per share (vs US$0.19 loss in 1Q 2021)

Miromatrix Medical Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings released: US$1.28 loss per share (vs US$4.76 loss in FY 2020)

Miromatrix Names Jim Douglas as New Chief Financial Officer

Miromatrix Medical Inc. Submits Pre-IND Request to the FDA for its External Liver Assist Product to Treat Acute Liver Failure

Third quarter 2021 earnings released: US$0.25 loss per share

Miromatrix Announces the First Successful Transplant of A Bioengineered Whole Organ in A Large Animal

Independent Director Ronald Eibensteiner has left the company

Independent Director Mark Wagner has left the company

Miromatrix Medical Inc. has completed an IPO in the amount of $43.2 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin